Transplanted hypoimmune (HIP)-modified allogeneic CD19-targeted CAR-T cells control CD19+ tumor cells in fully immunocompetent allogeneic humanized mice, evading both the adaptive and innate immune systems

Allogeneic HIP CAR T cells can be produced on a large scale and with high gene editing efficiency using the novel gene editing platform CRISPR/Cas12b

HIP-modified allogeneic BCMA-targeted CAR-T cells demonstrate efficacy and cytokine production against BCMA+ target cells against multiple myeloma in vitro

Fusosomes specifically transduce primary, non-activated CD8+ T cells to generate highly functional CAR T cells capable of eliminating CD19+ tumor cells in animal models with two dosing strategies

SEATTLE, December 11, 2022 (GLOBE NEWSWIRE) — Sana Biotechnology, Inc. SANAa company focused on the development and delivery of genetically engineered cells as medicines shared data in six presentations at the 64th…^th American Society of Hematology (ASH) Annual Meeting and Exposition, held Saturday, December 10-Tuesday, December 13, 2022 in New Orleans, LA, highlighting continued advances in key technologies in support of Sana ex vivo allogeneic CAR-T cell programs and in vivo Platform.

“Our HIP platform has the potential to transform the CAR-T field and thereby the treatment of hematological malignancies, and we are excited to share data from multiple drug candidates ahead of our planned entry into the clinic in 2023,” said Terry Fry , MD, Senior Vice President and Head of T Cell Therapeutics at Sana. “Separate oral presentations show that our HIP-modified allogeneic CD19-targeted CAR-T cells can evade immune recognition and kill tumor cells in a fully immunocompetent preclinical model, including serial ones in vivo tumor stimulation and that our manufacturing process is capable of reproducibly producing HIP-modified allogeneic CAR-T cells on a large scale with high gene editing efficiency and yield. We intend to fully develop this platform to treat patients with lymphoma, leukemia and multiple…